Top

Supportive Care in Cancer

Published in:

01-09-2008 | Original Article

The acute effect of tropisetron on ECG parameters in cancer patients

Authors: Ozlem Yavas, Mehmet Yazici, Onder Eren, Cem Boruban, Mehmet Artac, Mine Genc

Published in: Supportive Care in Cancer | Issue 9/2008

Abstract

Objectives

The 5-hydroxytryptamine 3 receptor antagonists, including tropisetron, ondansetron, granisetron, and dolasetron are agents used effectively for supportive care. They are used for the prevention and treatment of chemotherapy and radiotherapy-induced emesis. Despite their overall excellent safety profile, some electrocardiographic changes related to heart rate and repolarization were reported. Ondansetron, granisetron, and dolasetron were studied on this manner. But to our knowledge, there is no information about the cardiac side effects of tropisetron. In this study, we aimed to determine the acute effects of tropisetron on ECG parameters related to repolarization, heart rate, and systemic blood pressure.

Materials and methods

Fifty-five cancer patients who received tropisetron for the prevention of acute chemotherapy-induced nausea and vomiting were enrolled into this single center, prospective study. Standard 12-lead ECG recordings were performed at baseline and 30 min after tropisetron (5 mg given over 1 min IV bolus) administration. P wave durations and corrected QT intervals were measured; P wave dispersion and QTc dispersion were calculated.

Results

In comparison with baseline, mean heart rate significantly decreased 30 min after administration of tropisetron. Tropisetron did not result in a significant change in P wave duration, corrected QT interval, P dispersion, and QTc dispersion.

Conclusion

In this study, tropisetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities. Only it may cause a slight decrease in heart rate.

Aapro M, Bourke JP (2003) Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer 39(7):927–931PubMedCrossRef

Antzelevitch C, Yan GX, Shimizu W (1999) Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol 32(Suppl):158–165PubMedCrossRef

Audhuy B, Cappelaere P, Martin M et al (1996) A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A(5):807–813PubMed

Ballard HS, Bottino G, Bottino J (1992) Ondansetron and chest pain. Lancet 340(8827):1107PubMedCrossRef

Bazett HR (1920) An analysis of the time relations of electrocardiographs. Heart 7:353–370

Benedict CR, Arbogast R, Martin L et al (1996) Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 28(1):53–59PubMedCrossRef

Boike SC, Ilson B, Zariffa N et al (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54(10):1172–1176PubMed

Buyukavci M, Olgun H, Ceviz N (2005) The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28(2):201–204PubMedCrossRef

Chen A, Kusumoto FM (2004) QT dispersion: much ado about something. Chest 125(6):1974–1977PubMedCrossRef

10.

Day CP, McComb JM, Campbell RW (1990) QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 63(6):342–344PubMedCrossRef

11.

Gialafos JE (1999) P-wave dispersion. Eur Heart J 20(4):317PubMedCrossRef

12.

Gray GW, McLellan TM, Ducharme MB (1996) Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 67(8):759–761PubMed

13.

Hesketh P, Navari R, Grote T et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14(8):2242–2249PubMed

14.

Hunt TL, Cramer M, Shah A et al (1995) A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35(7):705–712PubMed

15.

Jantunen IT, Kataja VV, Muhonen TT et al (1996) Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37(5):502–504PubMedCrossRef

16.

Keefe DL (2002) The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern. Oncologist 7(1):65–72PubMedCrossRef

17.

Kuryshev YA, Brown AM, Wang L et al (2000) Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 295(2):614–620PubMed

18.

Lofters WS, Pater JL, Zee B et al (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15(8):2966–2973PubMed

19.

Morganroth J (2007) Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 81(1):108–113PubMedCrossRef

20.

Morganroth J (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res Found Workshop (59):171–184

21.

Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agents. J Support Oncol 1(2):89–103PubMedCrossRef

22.

Perkiomaki JS et al (1997) Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol 30(5):331–338CrossRef

23.

Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8(2):187–198PubMedCrossRef

Title: The acute effect of tropisetron on ECG parameters in cancer patients
Authors: Ozlem Yavas
Mehmet Yazici
Onder Eren
Cem Boruban
Mehmet Artac
Mine Genc
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 9/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0400-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2008

Changes in quality of life and its related factors in liver cancer patients receiving stereotactic radiation therapy

Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain

The use and toxicity of steroids in the management of patients with brain metastases

Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern

Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders

Patient–oncologist communication in advanced cancer: predictors of patient perception of prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer